Current and evolving standards of care for patients with ARDS.

The key secondary endpoint of death or crossover to ECMO was highly significant, most other secondary endpoints favored the ECMO group, and adverse events were evenly distributed, leading editorialists to suggest that ‘ECMO probably has some benefit in this context, despite the trial not being traditionally positive’ [ 85 ].

also in 132,142 other papers